Xintela AB
Develops stem cell therapies for osteoarthritis and venous leg ulcers using proprietary technology.
XINT | ST
Overview
Corporate Details
- ISIN(s):
- SE0007756903 (+2 more)
- LEI:
- 549300SMDH1EOLCBQU68
- Country:
- Sweden
- Address:
- MEDICON VILLAGE, 223 81 Lund
- Website:
- https://xintela.se/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Xintela AB is a biopharmaceutical company developing medical treatments in regenerative medicine and targeted cancer therapy. The company's technology is based on its proprietary cell surface marker, integrin α10β1. Its primary focus is on stem cell-based therapies for conditions with high unmet medical needs. The lead product, XSTEM®, is a stem cell therapy in clinical development (Phase I/IIa) for treating knee osteoarthritis and difficult-to-heal venous leg ulcers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Xintela AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Xintela AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
